Boltjes André, Dömling Alexander
Department of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, The Netherlands.
Eur J Chem. 2019 Nov 14;2019(42):7007-7049. doi: 10.1002/ejoc.201901124. Epub 2019 Aug 30.
Imidazo[1,2-]pyridine is a well-known scaffold in many marketed drugs, such as Zolpidem, Minodronic acid, Miroprofen and DS-1 and it also serves as a broadly applied pharmacophore in drug discovery. The scaffold revoked a wave of interest when Groebke, Blackburn and Bienaymé reported independently a new three component reaction resulting in compounds with the imidazo[1,2-]-heterocycles as a core structure. During the course of two decades the Groebke Blackburn Bienaymé (GBB-3CR) reaction has emerged as a very important multicomponent reaction (MCR), resulting in over a hundred patents and a great number of publications in various fields of interest. Now two compounds derived from GBB-3CR chemistry received FDA approval. To celebrate the first 20 years of GBB-chemistry, we present an overview of the chemistry of the GBB-3CR, including an analysis of each of the three starting material classes, solvents and catalysts. Additionally, a list of patents and their applications and a more in-depth summary of the biological targets that were addressed, including structural biology analysis, is given.
咪唑并[1,2 - ]吡啶是许多已上市药物中熟知的骨架结构,如唑吡坦、米诺膦酸、米洛芬和DS - 1,它在药物研发中也是一种广泛应用的药效基团。当格罗布克、布莱克本和比奈梅各自独立报道一种新的三组分反应,该反应生成以咪唑并[1,2 - ]杂环为核心结构的化合物时,这种骨架结构引起了广泛关注。在二十年的时间里,格罗布克 - 布莱克本 - 比奈梅(GBB - 3CR)反应已成为一种非常重要 的多组分反应(MCR),产生了一百多项专利以及众多在各个感兴趣领域的出版物。现在,两种源自GBB - 3CR化学的化合物已获得美国食品药品监督管理局(FDA)批准。为庆祝GBB化学的首个二十年,我们概述了GBB - 3CR的化学,包括对三类起始原料、溶剂和催化剂的分析。此外,还列出了专利及其应用,并对所涉及的生物学靶点进行了更深入的总结,包括结构生物学分析。